-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
CCTV News’ Live Broadcast “Taking New Steps” Visits Shijiazhuang Sihua Pharmaceutical Group
Category:
发布时间：2024-01-04
【概要描述】
To feel the solid confidence behind the new strides of the New Year and to experience the innovative drive and dynamic vitality of “new-quality productivity,” on January 3, CCTV News’ large-scale New Year live special report, “Taking New Steps,” produced by China Media Group, visited the Pharmaceutical Research Institute of Shijiazhuang Sihua Pharmaceutical Group. The program explored how Shijiazhuang Sihua is reinventing itself and forging ahead with innovation, accelerating its transformation into high-quality development under the leadership of innovation, and witnessed the vibrant pulse of Hebei’s booming pharmaceutical industry.
To feel the solid confidence behind the new strides of the New Year and to experience the innovative drive and dynamic vitality of “new-quality productivity,” on January 3, CCTV News’ large-scale New Year live special report, “Taking New Steps,” produced by China Media Group, visited the Pharmaceutical Research Institute of Shijiazhuang Sihua Pharmaceutical Group. The program explored how Shijiazhuang Sihua is reinventing itself and forging ahead with innovation, accelerating its transformation into high-quality development under the leadership of innovation, and showcased the remarkable achievements of this transformation—while also capturing the vibrant pulse of Hebei’s booming pharmaceutical industry.
As one of China’s top 100 pharmaceutical companies and a leading domestic manufacturer of injectable formulations, Shijiazhuang Sihua Pharmaceutical has fully, accurately, and comprehensively implemented the new development philosophy. Guided by national development strategies and market demand, the company has seized growth opportunities, invested in emerging areas, built new competitive advantages, and vigorously advanced technological self-reliance and strength. This has ushered in a new phase of iterative product development, encompassing specialty and high-end complex generic drugs, innovative medicines, improved new drugs, active pharmaceutical ingredients, biologics, and pharmaceutical packaging materials. Continuous innovation has accelerated the company’s move toward high-quality, sustainable growth, significantly enhancing its scale, innovation capacity, brand reputation, and market influence. Its products are now marketed in more than 100 countries and regions worldwide, powerfully driving a remarkable transformation—from a business model dominated by a single injectable product to diversified development across the entire industry chain.
Since last year, Shijiazhuang Sihua Pharmaceutical has made it its mission to research, develop, and manufacture high-quality “Made in China” pharmaceuticals, breaking new ground and fostering the growth of new drivers of productivity. The company has focused on overcoming critical technological bottlenecks in the development of shortage drugs and treatments for rare diseases, resulting in the approval of a total of 88 new products—more than double the number approved in 2022. Its R&D quality and efficiency now lead the industry, its innovation capabilities have been significantly enhanced, and its momentum toward joining the forefront of domestic pharmaceutical innovation continues to strengthen.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091